Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology
March 15, 2017 09:56 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, March 15, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced the publication today of the rationale and design for the company’s REDUCE-IT...
Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations
February 28, 2017 06:00 ET
|
Amarin Corporation plc
$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015 REDUCE-IT Cardiovascular Outcomes...
Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017
February 22, 2017 08:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
February 09, 2017 07:49 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes
January 20, 2017 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) (“Amarin”) announced today that it and its wholly owned subsidiary, Corsicanto II...
Amarin Provides Preliminary 2016 Results and 2017 Outlook
January 05, 2017 16:01 ET
|
Amarin Corporation plc
Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range Anticipate Full-Year 2017 Net Product Revenues Between $155 Million...
Amarin Announces Contractual Reminder of Optional Put to Holders of $15.1 million Principal Amount of Outstanding 3.50% Exchangeable Senior Notes Due 2032
December 16, 2016 16:31 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (the “Company”) announced today that it is providing a contractual reminder to holders of...
Pure EPA Vascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides
November 14, 2016 19:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an oral presentation at the American Heart Association Scientific...
Amarin to Present at the Jefferies 2016 London Healthcare Conference
November 11, 2016 10:26 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations
November 03, 2016 05:30 ET
|
Amarin Corporation plc
Third Quarter Net Product Revenue Up 52% vs. Prior Year PeriodMaintaining Guidance on 2016 Net Product Revenue at $112-$125 Million;Anticipate Upper Half of RangeManagement to Host Conference Call at...